Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: A meta-analysis of randomized controlled trials

Cardiovascular Drugs and Therapy

Volumn 27, Issue 1, 2013, Pages 23-35

  Kwong, Joey S W ^a   Lam, Yat Yin ^a   Yan, Bryan P ^a   Yu, Cheuk Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anticoagulants; Atrial fibrillation; Hemorrhage; Meta analysis; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; ATECEGATRAN METOXIL; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DATA INTERPRETATION, STATISTICAL; FACTOR XA; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84873059447     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6426-9     Document Type: Review

References (68)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:e101-98.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-8.
3. Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol. 2010;25:312-20.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.
5. Lam YY, Ma TKW, Yan BP. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. Int J Cardiol. 2011;150:4-11.
6. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Euro Heart Survey Investigators, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018-26.
7. Lip GYH. Atrial fibrillation in 2011: stroke prevention in AF. Nat Rev Cardiol. 2012;9:71-3.
8. Ezekowitz MD, Aikens TH, Brown A, Ellis Z. The evolving field of stroke prevention in patients with atrial fibrillation. Stroke. 2010;41:S17-20.
9. Bassand JP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace. 2012;14:312-24.
10. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011;127:S5-S12.
11. Stewart RA. Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. Curr Opin Cardiol. 2011;26:294-9.
12. Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, et al. Novel anticoagulants for stroke prevention in atrial fibrillation current clinical evidence and future developments. J Am Coll Cardiol. 2010;56:2067-76.
13. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011;105:574-8.
14. Potpara TS, Lip GY, Apostolakis S. New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart. 2012;98:1341-7.
15. Piccini JP, Wallace TW, Patel MR, Becker RC. Stroke prevention in atrial fibrillation. Cardiovasc Drugs Ther. 2011;25:561-70.
16. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-60.
17. Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2012 Apr 9. [Epub ahead of print]. http://dx.doi.org/10.1016/j.ijcard.2012.03.148 (accessed June 7, 2012).
18. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4.
19. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407-18.
20. Apostolakis S, Lip GY. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. Expert Opin Investig Drugs. 2012;21:1057-64.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org (accessed June 7, 2012).
22. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
23. Turpie AGG, Lip GYH, Minematsu K, Goto S, Renfurm RW, Wong KSL. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study (abstract 1194). Eur Heart J. 2010;31 Suppl 1:173.
24. Lip GYH, Halperin JL, Petersen P, Rodgers GM, Renfurm RW. Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2) (Abstract O-TH-083). J Thromb Haemost. 2011;9 Suppl 2:748.
25. Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-51.
26. Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-8.
27. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-8.
28. Albers GW, Diener HC, Frison L, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-8.
29. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, ARISTOTLE Investigators, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-9.
30. Rosenson R, Horowitz J, Kaski J-C, Krum H, Remme WJ. Clinical trials update ESC congress 2011. Cardiovasc Drugs Ther. 2012;26:77-84.
31. Ezekowitz J, Dorian P, Granger C, Alexander J, Lopes R, Hanna M, for the ARISTOTLE Trialist Group, et al. Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: primary results of the ARISTOTLE trial. Can J Cardiol. 2011;27:S334.
32. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.
33. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study. Circ J. 2011;75:1852-9.
34. Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159:348-353.e1.
35. Alexander W. European Society of Cardiology congress 2012. PT. 2012;37:592-4.
36. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, AVERROES Steering Committee and Investigators, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17.
37. Connolly SJ, Ezekowitz MD, Diaz R, Hohnloser SH, Dorian P. A phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa). Presentation at the American College of Cardiology (ACC) 59th Annual Scientific Session; Atlanta, GA; 2010. http://www.cardiosource.org/News-Media/Meeting-Coverage/ACC/ ACC-2010.aspx?w-nav=Search&WT.oss=betrixaban&WT.oss-r=7&http://www. cardiosource.org/news-media/meeting-coverage/acc/acc-2010.aspx (accessed June 6, 2012).
38. Weitz JI, Connolly SJ, Patel L, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-41.
39. Chung N, Jeon HK, Lien LM, Lai WT, Tses HF, Chung WS, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost. 2011;105:535-44.
40. Hori M, Matsumoto M, Tanahashi N, Momomura SI, Uchiyama S, Goto S, and on behalf of the J-ROCKET AF study investigators, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J. 2012;76:2104-11.
41. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, and on behalf of the J-ROCKET AF Study Investigators, et al. J-ROCKET AF: the safety and efficacy of rivaroxaban for prevention of stroke in Japanese patients with nonvalvular atrial fibrillation (Abstract O-MO-032). J Thromb Haemost. 2011;9(Suppl s2):20.
42. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.e1.
43. Alexander W. American Heart Association 2010 Scientific Sessions and American Society of Nephrology: Renal Week 2010: 43rd Annual Meeting & Scientific Exposition. P T. 2011;36:46-7.
44. Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N, et al. Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail. 2011;13:460-5.
45. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
46. Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Steering Committee, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30:2897-907.
47. Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010;103:604-12.
48. Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Steering Committee, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res. 2011;127:91-9.
49. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol. 2007;100:1419-26.
50. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-10.
51. Cleland JGF, Coletta AP, Yassin A, Buga L, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail. 2009;11:1214-9.
52. Alexander W. European Society of Cardiology, 2009 Congress and a comparison of two asthma medications. P T. 2009;34:565-74.
53. Schirmer SH, van der Laan AM, Böhm M, Mahfoud F. Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol. 2009;98:691-9.
54. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
55. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-6.
56. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.
57. Strobeck JE. Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants. Cardiovasc Drugs Ther. 2012;26:331-8.
58. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
59. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263-72.
60. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.
61. Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-8.
62. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-80.
63. 2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660-7.
64. 2 score? Int J Cardiol. 2012;159:161-2.
65. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
66. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27:74-90.
67. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719-47.
68. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation- Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635-41.